CURAGEN AND TOPOTARGET BEGIN PXD101 AND VELCADE TRIAL
CuraGen Corporation and TopoTarget have announced the initiation of patient dosing in a Phase Ib/II proof-of-concept trial to evaluate PXD101, a small molecule histone deacetylase (HDAC) inhibitor, in combination with Velcade (bortezomib) for the treatment of relapsed, refractory multiple myeloma, a deadly form of blood cancer.
The goal of the Phase Ib portion of this trial is to establish the maximum tolerated dose (MTD) of PXD101 in combination with Velcade in up to 30 patients who have failed at least two prior lines of therapy for multiple myeloma. Following determination of the MTD, the study will enter Phase II and enroll up to 15 additional patients with relapsed, refractory multiple myeloma who have failed at least one prior therapy. The Phase II portion of the study will further evaluate the safety, pharmacokinetics, pharmacodynamics, and anti-tumor activity of PXD101 in combination with Velcade.